New Weight-Loss injection HDM1005 tested in small early trial
NCT ID NCT06637020
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new drug called HDM1005 in 40 overweight or obese adults. Participants received either the drug or a placebo as a shot under the skin. The main goal was to check safety and how the body processes the drug, not yet to prove it works for weight loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HDM1005 injection
- What this could lead to
- If this drug proves safe and effective in larger trials, it could become a new option for weight management in people with overweight or obesity.
- What could go wrong
- This is a very early phase 1 study with only 40 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss in later studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Can a Boron-Based pill tame obesity and blood sugar?
- Citrus flavonoid hesperidin put to the test as a brain booster for overweight adults
- Could dimming lights and early dinners boost insulin sensitivity?
- Extra sleep may boost insulin sensitivity and cut heart risk
- Can changing when and what you eat trick your body into making less fat?